Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jun;38(6):1303–1308. doi: 10.1128/aac.38.6.1303

Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.

J Berenguer 1, N M Ali 1, M C Allende 1, J Lee 1, K Garrett 1, S Battaglia 1, S C Piscitelli 1, M G Rinaldi 1, P A Pizzo 1, T J Walsh 1
PMCID: PMC188202  PMID: 8092829

Abstract

Itraconazole and amphotericin B were compared by using a newly developed model of invasive pulmonary aspergillosis in rabbits immunosuppressed with methylprednisolone and cyclosporin A (CsA). Both itraconazole at 40 mg/kg (given orally) and amphotericin B at 1 mg/kg (given intravenously) had in vivo antifungal activity in comparison with controls. At these dosages, amphotericin B was more effective than itraconazole in reducing the tissue burden (log10 CFU per gram) of Aspergillus fumigatus (P < 0.05) and the number of pulmonary lesions (P < 0.01). However, there was considerable variation in the near-peak concentrations of itraconazole in plasma (median, 4.15 micrograms/ml; range, < 0.5 to 16.8 micrograms/ml) and a strong inverse correlation between concentrations of itraconazole in plasma and the tissue burden of A. fumigatus. An inhibitory sigmoid maximum-effect model predicted a significant pharmacodynamic relationship (r = 0.87, P < 0.001) between itraconazole concentrations in plasma and antifungal activity as a function of the tissue burden of A. fumigatus. This model demonstrated that levels in plasma of greater than 6 micrograms/ml were associated with a significantly greater antifungal effect. Levels in plasma of less than 6 micrograms/ml were associated with a rapid decline in the antifungal effect. Itraconazole, in comparison with amphotericin B, caused a twofold elevation of CsA levels (P < 0.01) but was less nephrotoxic (P < 0.01). This study of experimental pulmonary aspergillosis demonstrated that amphotericin B at 1 mg/kg/day was more active but more nephrotoxic than itraconazole at 40 mg/kg/day, that itraconazole increased concentrations of CsA in plasma, and that the antifungal activity of itraconazole strongly correlated with concentrations in plasma in an inhibitory sigmoid maximum-effect model. These findings further indicate the importance of monitoring concentrations of itraconazole in plasma as a guide to increasing dosage, improving bioavailability, and optimizing antifungal efficacy in the treatment of invasive pulmonary aspergillosis.

Full text

PDF
1303

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boon A. P., O'Brien D., Adams D. H. 10 year review of invasive aspergillosis detected at necropsy. J Clin Pathol. 1991 Jun;44(6):452–454. doi: 10.1136/jcp.44.6.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Burch P. A., Karp J. E., Merz W. G., Kuhlman J. E., Fishman E. K. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol. 1987 Dec;5(12):1985–1993. doi: 10.1200/JCO.1987.5.12.1985. [DOI] [PubMed] [Google Scholar]
  3. Denning D. W., Follansbee S. E., Scolaro M., Norris S., Edelstein H., Stevens D. A. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med. 1991 Mar 7;324(10):654–662. doi: 10.1056/NEJM199103073241003. [DOI] [PubMed] [Google Scholar]
  4. Denning D. W., Stevens D. A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990 Nov-Dec;12(6):1147–1201. doi: 10.1093/clinids/12.6.1147. [DOI] [PubMed] [Google Scholar]
  5. Denning D. W., Tucker R. M., Hanson L. H., Hamilton J. R., Stevens D. A. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med. 1989 Oct;149(10):2301–2308. [PubMed] [Google Scholar]
  6. Denning D. W., Tucker R. M., Hanson L. H., Stevens D. A. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989 Jun;86(6 Pt 2):791–800. doi: 10.1016/0002-9343(89)90475-0. [DOI] [PubMed] [Google Scholar]
  7. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol. 1990 Sep;23(3 Pt 2):607–614. doi: 10.1016/0190-9622(90)70263-h. [DOI] [PubMed] [Google Scholar]
  8. Grant S. M., Clissold S. P. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989 Mar;37(3):310–344. doi: 10.2165/00003495-198937030-00003. [DOI] [PubMed] [Google Scholar]
  9. Graybill J. R., Ahrens J. Itraconazole treatment of murine aspergillosis. Sabouraudia. 1985 Jun;23(3):219–223. doi: 10.1080/00362178585380321. [DOI] [PubMed] [Google Scholar]
  10. Hector R. F., Yee E. Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. Antimicrob Agents Chemother. 1990 Mar;34(3):448–454. doi: 10.1128/aac.34.3.448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Heykants J., Van Peer A., Van de Velde V., Van Rooy P., Meuldermans W., Lavrijsen K., Woestenborghs R., Van Cutsem J., Cauwenbergh G. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32 (Suppl 1):67–87. doi: 10.1111/j.1439-0507.1989.tb02296.x. [DOI] [PubMed] [Google Scholar]
  12. Hostetler J. S., Hanson L. H., Stevens D. A. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother. 1992 Feb;36(2):477–480. doi: 10.1128/aac.36.2.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kennedy M. S., Deeg H. J., Siegel M., Crowley J. J., Storb R., Thomas E. D. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation. 1983 Mar;35(3):211–215. doi: 10.1097/00007890-198303000-00005. [DOI] [PubMed] [Google Scholar]
  14. Kirkland T. N., Fierer J. Cyclosporin A inhibits Coccidioides immitis in vitro and in vivo. Antimicrob Agents Chemother. 1983 Dec;24(6):921–924. doi: 10.1128/aac.24.6.921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kramer M. R., Marshall S. E., Denning D. W., Keogh A. M., Tucker R. M., Galgiani J. N., Lewiston N. J., Stevens D. A., Theodore J. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med. 1990 Aug 15;113(4):327–329. doi: 10.7326/0003-4819-113-4-327. [DOI] [PubMed] [Google Scholar]
  16. Kwan J. T., Foxall P. J., Davidson D. G., Bending M. R., Eisinger A. J. Interaction of cyclosporin and itraconazole. Lancet. 1987 Aug 1;2(8553):282–282. doi: 10.1016/s0140-6736(87)90873-7. [DOI] [PubMed] [Google Scholar]
  17. Le Conte P., Joly V., Saint-Julien L., Gillardin J. M., Carbon C., Yeni P. Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis. Am Rev Respir Dis. 1992 Feb;145(2 Pt 1):424–429. doi: 10.1164/ajrccm/145.2_Pt_1.424. [DOI] [PubMed] [Google Scholar]
  18. Meffin P. J., Winkle R. A., Blaschke T. F., Fitzgerald J., Harrison D. C., Harapat S. R., Bell P. A. Response optimization of drug dosage: antiarrhythmic studies with tocainide. Clin Pharmacol Ther. 1977 Jul;22(1):42–57. doi: 10.1002/cpt197722142. [DOI] [PubMed] [Google Scholar]
  19. Nováková I., Donnelly P., de Witte T., de Pauw B., Boezeman J., Veltman G. Itraconazole and cyclosporin nephrotoxicity. Lancet. 1987 Oct 17;2(8564):920–921. doi: 10.1016/s0140-6736(87)91412-7. [DOI] [PubMed] [Google Scholar]
  20. Persat F., Marzullo C., Guyotat D., Rochet M. J., Piens M. A. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer. 1992;28A(4-5):838–841. doi: 10.1016/0959-8049(92)90127-n. [DOI] [PubMed] [Google Scholar]
  21. Rose H. D., Varkey B. Deep mycotic infection in the hospitalized adult: a study of 123 patients. Medicine (Baltimore) 1975 Nov;54(6):499–507. doi: 10.1097/00005792-197511000-00004. [DOI] [PubMed] [Google Scholar]
  22. Schmitt H. J., Edwards F., Andrade J., Niki Y., Armstrong D. Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis. Chemotherapy. 1992;38(2):118–126. doi: 10.1159/000238951. [DOI] [PubMed] [Google Scholar]
  23. Smith D., van de Velde V., Woestenborghs R., Gazzard B. G. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol. 1992 Jul;44(7):618–619. doi: 10.1111/j.2042-7158.1992.tb05478.x. [DOI] [PubMed] [Google Scholar]
  24. Trenk D., Brett W., Jähnchen E., Birnbaum D. Time course of cyclosporin/itraconazole interaction. Lancet. 1987 Dec 5;2(8571):1335–1336. doi: 10.1016/s0140-6736(87)91232-3. [DOI] [PubMed] [Google Scholar]
  25. Tricot G., Joosten E., Boogaerts M. A., Vande Pitte J., Cauwenbergh G. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S94–S99. doi: 10.1093/clinids/9.supplement_1.s94. [DOI] [PubMed] [Google Scholar]
  26. Tucker R. M., Denning D. W., Hanson L. H., Rinaldi M. G., Graybill J. R., Sharkey P. K., Pappagianis D., Stevens D. A. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992 Jan;14(1):165–174. doi: 10.1093/clinids/14.1.165. [DOI] [PubMed] [Google Scholar]
  27. Van Cutsem J., Van Gerven F., Janssen P. A. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S15–S32. doi: 10.1093/clinids/9.supplement_1.s15. [DOI] [PubMed] [Google Scholar]
  28. Viviani M. A., Tortorano A. M., Pagano A., Vigevani G. M., Gubertini G., Cristina S., Assaisso M. L., Suter F., Farina C., Minetti B. European experience with itraconazole in systemic mycoses. J Am Acad Dermatol. 1990 Sep;23(3 Pt 2):587–593. doi: 10.1016/0190-9622(90)70260-o. [DOI] [PubMed] [Google Scholar]
  29. Walsh T. J., Bacher J., Pizzo P. A. Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci. 1988 Aug;38(4):467–471. [PubMed] [Google Scholar]
  30. Walsh T. J. Invasive pulmonary aspergillosis in patients with neoplastic diseases. Semin Respir Infect. 1990 Jun;5(2):111–122. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES